Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 19, 2023 3:00pm
143 Views
Post# 35403599

RE:RE:RE:RE:RE:Thoughts on AACR Posters -- overall, very good DELTAs.

RE:RE:RE:RE:RE:Thoughts on AACR Posters -- overall, very good DELTAs.If TH1902 indeed stop working after one or two weeks I would guess it is not because of lack of only internalizations as they did have off targeted delivery resulting in side effects so I would think the drug internalizes in both healthy and cancerous cells under constant pressure will eventually develop “acquired resistance” to the cytotoxic agents due to mutations among others. During the trial the cycles were on constant basis every 3 weeks followed by similar time period for their analysis (rest time), however they did mention in previous CPs other alternatives such as weekly and intermittent dosing. The idea about on/off or high/low dosing is the adaptive dosing may interrupt the growth of drug-dependent resistant cancerous cells which seems be an alternative route of dosing schedule  for traditional chemo and I can’t see why it cannot be applied to targeted therapy. We will see whether the new dosing strategies after the restart would consider any of these.
<< Previous
Bullboard Posts
Next >>